The Relative Strength (RS) Rating for SpringWorks Therapeutics (SWTX) stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
↑ XThis exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating of above 80 as they begin their largest price moves. See if SpringWorks Therapeutics stock can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
SpringWorks Therapeutics stock recently reclaimed its 50-day moving average and not in a proper buying range. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The biotech company reported 0% EPS growth in the latest quarterly report. Revenue increased 0%.
SpringWorks Therapeutics stock holds the No. 79 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Exelixis (EXEL) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.